{"anticipatedPostingDate":"2027-01","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"Cycles 1, 3, 5, 7, 12, and 24 : Predose on Day 1; EOT (37.11 months); and 8 weeks after the last daratumumab dose (up to 38.11 months). Each Cycle was 28 days","title":"Number of Participants With Anti-Recombinant Human Hyaluronidase (rHuPH20) Antibodies","type":"SECONDARY"}